VGL101
Sponsors
Vigil Neuroscience Inc., Vigil Neuroscience, Inc.
Conditions
ALSPLeukoencephalopathy
Phase 2
A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
TerminatedNCT05677659
Start: 2022-12-14End: 2025-06-04Updated: 2025-06-11
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP)
CompletedCTIS2022-502505-15-00
Start: 2023-11-09End: 2025-06-04Target: 7Updated: 2025-01-28